July 20, 2023—RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Limited, a clinical-stage immuno-oncology company headquartered in Sydney, Australia, announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s transarterial microperfusion (TAMP) therapy platform for the treatment of difficult-to-access tumors.
As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.